Raplon
Company: Organon
Approval Status: Approved August 1999
Treatment for: Pharmacology
Areas: Pharmacology/Toxicology
General Information
Raplon (rapacuronium bromide) has been approved as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures. Raplon was proven in studies to be an effective alternative to succinylcholine with a rapid onset and a short duration of action with the recommended dose.
Raplon is the first and only nondepolarizing neuromuscular blocking agent (NMBA) that combines both rapid onset with short duration for tracheal intubations and many short procedures including appendectomy, tonsillectomy, cystectomy, tubal ligation, and Cesarean section.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
